

DECLARATION OF EMILIO MANTERO-ATIENZA, M.D.

I, Emilio Mantero-Atienza, M.D., declare under penalty of perjury:

1. I am a board certified psychiatrist and author with over 30 years of experience working with patients who suffer from behavioral health issues.
2. I specialize in medication assisted therapies, medication assisted treatment in mental health services, and evidence based treatment.
3. I have also obtained Ph.D. in clinical biochemistry.
4. I practice medicine at Mercy Hospital, Miami Kendall Regional, and most recently, Southern Winds Hospital.
5. During my residency, I worked with the Miami VA Healthcare System where I learned how to treat patients suffering from Post-Traumatic Stress Disorder (PTSD)
6. Thereafter, I have treated many patients who have suffered from PTSD throughout my career. PTSD often impairs the major life activities of patients, including work, family life, and relationships.
7. My C.V. is attached hereto.
8. A significant portion of my practice has been devoted to treating patients who suffer from Substance Use Disorder. Substance use disorders impair the major life activities of patients including work, family life, and relationships.
9. I have reviewed Quality of Life Corp.'s (d/b/a Margate Care for Heroes) ("MCH") business plan and I have viewed photographs of the facility.
10. For years, I have also had many discussions with Ms. Miryam Jimenez regarding the facility, and I agree to provide care and services in the MCH facility if the City permits it to open.
11. The facility that MCH plans to open is not a hospital and would not require hospital licensing. Rather, it is a residential treatment facility that would provide care and services at a subacute level, rather than at an acute level.
12. If the City allows MCH to open, I would endeavor to provide the best possible care to veterans at MCH.
13. Subacute treatment for people in recovery is best accomplished at a facility like MCH's where the clients have a substantial support group of individuals who have endured similarly traumatic events and can progress through treatment together.
14. I support MCH's application to open the residential treatment facility for veterans in Margate.

15. I believe the City should support veterans by approving MCH's application so my colleagues and I may continue to provide much needed medical care and services to one of our nation's most vulnerable populations.

Dated this 20th day of July 2020.

Emilio Mantero-Atienza M.D.
Emilio Mantero-Atienza, M.D.

CURRICULUM VITAE

EMILIO MANTERO-ATIENZA, M.D. PH. D.

Personal:

Main Office address: 1901 S.W. 1st Street, 2nd Floor Suite 208
Miami, Florida 33135
Phone: (305) 326-0729 Fax: (305) 326-0077
Second Location: 1200 Alton Road
Miami Beach, Florida 33139
Phone: (305) 534-3242 Fax: (305) 531-8075

Education:

Oct, 1975- Sept, 1981 M.D. (Medicine)
University of Sevilla School of Medicine, Sevilla, Spain
Aug.1986-June1988 Master in Public Health and Epidemiology (MPH)
University of Miami School of Medicine, Miami, Florida
June1983-Dec.1990 Ph.D. (Clinical Biochemistry)
University of Sevilla School of Medicine, Sevilla, Spain

11. Post Doctoral Education:

Sep 1981- June 1985, Medicine, National Institute of Health, Madrid, Spain

July 1985- July 1988, Pharmacology
Department of Pharmacology, University of Miami School of Medicine, Miami, Florida
August 1986- August1988, Nutrition and Biochemistry
Department of Epidemiology and Public Health, Nutrition Division, University of
Miami School of Medicine, Miami, Florida
August 1986- August 1988, Epidemiology
Department of Epidemiology and Public Health, University of Miami School of
Medicine, Miami, Florida
January 1991- December 1994, Psychiatry
Department of Psychiatry, University of Miami School of Medicine/Jackson Memorial
Hospital, Miami, Florida
June 1993- June1995, Alcoholism and Addiction Medicine
Department of Psychiatry, University of Miami School of Medicine/Jackson Memorial
Hospital, Miami, Florida

Board Certification & Licensure:

ECFMG Certification	1990
FLEX Certification	1990
State of Florida Board Medicine	1992
American Board of Psychiatry and Neurology (BE)	1994
American Board of Forensic Examiners (BC)	1996
Buprenorphine (Suboxone) Treatment of Opioid Dependence Certificate # XM3197301	2013

Hospital Privileges:

Mercy Hospital
Jackson Memorial Hospital
Kendall Regional Medical Center

Professional Experience:

1981-1982	Staff Physician, "Gomez Ulla" Medical Center, Madrid, Spain
1982-1982	Staff Physician, National Institute of Health, Madrid, Spain
1983-1984	Staff Physician, National Institute of Health, Sevilla, Spain
1982-1984	Staff Physician Department of Oncology Regional Center "Duques del Infantado", Spanish Association against Cancer, Sevilla, Spain
1984-1985	Clinical Research Study Coordinator, Clinical Pharmacology Associates, Miami, Florida
1985-1987	Research Associate, Department of Pharmacology, University of Miami School of Medicine, Miami, Florida
1987-1988	Fellow, American Heart Assoc., Florida Affiliate, Department of Pharmacology, University of Miami School of Medicine, Miami, Florida
1989-1991	Research Assistant Professor, Department of Epidemiology, University of Miami School of Medicine, Miami, Florida
1989-1991	Director Nutrition Division, Department of Epidemiology and Public Health, University of Miami School of Medicine, Miami, Florida
1989-1992	Associate Director for Education and Training NIH/Fogarty International Graduate Training Program
1991-1994	Resident in Psychiatry, Jackson Memorial Hospital, University of Miami School of Medicine, Miami, Florida
1993-1995	Research Fellow, Alcohol Disorders Research Unit, Department of Psychiatry, Univ. Of Miami School of Medicine
1991-1995	Clinical Assistant Professor, Department of Epidemiology and Public Health,
1995-1996	University of Miami School of Medicine, Miami, Florida
	Attending Physician, Alcohol Disorders Research Unit, Department of Psychiatry
1995-2020	Private Practice, University of Miami Medical Center (West Building) 1321 N.W. 14 Street Suite # 501. Miami, Florida

1999-2001 Medical Director, General Psychiatry Unit; Windmoor Hospital, Miami, Florida
2003-2007 Medical Director, and Chairman/Vice Chairman, Department of Psychiatric service at Cedars Medical Center. Miami, Florida

2008-2009 Medical Director for the Department of Psychiatry services at University of Miami Hospital

2011-2012 Kendall Regional Medical Center Graduate Medical Educating Voting Member

2011-2013 Deputy Director of Psychiatry Teaching Services at American University of the Caribbean (in Florida) teaching provided at the University of Miami Hospital

2011-2013 Deputy Director of Psychiatry Teaching Services Ross University (in Florida) teaching provided at the University of Miami Hospital

2011-2017 Medical Director of Psychiatry and Behavioral Sciences at Kendall Regional MedicalCenter. Miami, Florida

2012-2016 Medical Director Behavioral Unit Mercy hospital

2014-2015 Medical Director, The Gardens Wellness Center North Miami, Florida 33162

2015-2018 Medical Director, Recovery Institute of South Florida Ft. Lauderdale, Florida 33316

1995-Present Medical Director of Miami Beach Medical Group and Wellness Center

2008-Present Medical Director and Chairman of Miami Dade Community Mental Health Center A Non-For-Profit Miami FL

2012-Present Principal Investigator and Founder of Premier Clinical Research Institute Miami FL

2017-Present Medical Director Recovery Project Detox Unit, PHP And IOP Programs Hollywood FL

2018-Present Director of Utilization Review and Case Management Programs Southern Winds Hospital Miami FL

2019-Present Medical Director Victory Recovery PHP And IOP Program Fort Lauderdale FL

2019- Present Medical Director Geriatric Unit at Southern Winds Hospital Miami FL

Teaching Responsibilities:

1986-1988 Regular Scheduled Seminar, Dept. of Pharmacology, University of Miami School of

Medicine

1987-1989	Lecturer in Basic Nutrition, Trinity Senior High School Level, Dade County, Florida
1987-1989	Lecturer in Nutrition, Senior College Level, Florida International University, Miami, Florida
1988-1989	Lecturer in Nutrition Metro-Dade Police Department, Miami, Florida
1989-1993	Instructor, Public Health Nutrition, Master Program in Public Health, Department of Epidemiology, University of Miami School of Medicine.
1989-1993	Instructor, Geriatric Education Center, Department of Psychiatry, University of Miami School of Medicine.
2003-2005	Associate Professor at Ross University Medical School. Miami, Florida
2011-2012	Kendall Regional Medical Center Graduate Medical Educating Voting Member
2011-2013	Clinical Professor of Psychiatry at AUC Medical School
2011-2013	Clinical Professor of Psychiatry at Ross University Medical School

Grants Received:

1986-1991	NIH/NIMH 1-P50-MH42555, Co-P.I., Total Award \$100,000
1988-1991	NIH/NIMH 1-P50-MH42555, Co-P.I. Total Award \$64,971
1987-1988	American Heart Association Florida Affiliate, Inc., P.I. Total Award \$25,000
1988-1989	American Heart Association Florida Affiliate, Inc., P.I. Total Award \$25,000
1987-1989	American Heart Association Florida Affiliate, Inc., Co P.I. Total Award \$28,000
1988-1993	NIH and Fogarty International Center, Investigator, Total Award \$1,640,115
1988-1991	Human Health Services, Investigator, Total Award \$948,964
1988-1989	Florida Cystic Fibrosis Foundation, Investigator, Total Award \$47,430
1988-1989	Florida Cystic Fibrosis Foundation, P.I., Total Award \$49,653
1989-1992	NIH-NINCDS, R29 NS 25785, Co-P.I., Total Award \$355,167
1993-1995	NIAAA Investigator Award, Total Award \$154,000

Honors and Awards:

1984	Postdoctoral work in Medicine and Surgery, completed with honors
1987	N.I.H. Postdoctoral Fellowship
1987	Citizen Ambassador, Division of International Ambassador Program
1987-1988	American Heart Association, Florida Affiliate, Clinician Scientist Award
1988-1989	American Heart Association, Florida Affiliate, Clinician Scientist Award
1988	Research Fellow in Clinical Nutrition
1988	Editorial Board of Archives of AIDS Research
1989	Elected Member Society Latin American Clinical Nutrition
1990	Founding Fellow of the Southern Association for Geriatric Medicine
1990	Elected Member Southern Medical Association
1991	Elected Fellow of the American College of Clinical Pharmacology
1992	Elected Member American Society Clinical Nutrition
1993	Grantsmanship Training Workshop for New Investigator Award, NIAAA
1993-1995	National Institute of Alcohol Abuse and Alcoholism (NIAAA) Investigator Award

1996 Elected Member Fellow of the American Board of Forensic Examiners

Professional Organizations:

1985 Southeastern Pharmacology Society
1987 American Public Health Association
1987 Florida Public Health Association
1987 New York Academy of Science
1987 American Council on Science and Health
1988 Physicians for a National Health Program
1988 American College Clinical Pharmacology
1988 National Council for International Health
1989 Sociedad Latinoamericana de Nutricion
1991 American Medical Association
1991 Florida Medical Association
1991 South Eastern Medical Society
1991 American Psychiatric Association
1991 Florida Psychiatric Association
1992 American Institute of Nutrition
1992 American Society for Clinical Nutrition
1995 American Society of Addiction Medicine
1996 American Board of Forensic Examiners

Community Services:

AIDS Watch South Florida, 1989
AIDS Epidemiology Research Cable-TAD Program, 1989
Seminars in Community based organizations:
Chronic Fatigue Syndrome Association, 1989, 1990
Cure AIDS Now, 1989, 1991
Body Positive Resource Center, 1989, 1992
Biopsychosocial Center for Studies on AIDS, 1991, 1992, 1993, 1994

SCIENTIFIC ARTICLES IN REFEREED JOURNALS:

1. Beach RS, **Mantero-Atienza E**, Eisdorfer C, Fordyce-Baum MK. Altered Folate Metabolism in Early HIV Infection. JAMA, 259:3128-9, 1988.
2. Beach RS, **Mantero-Atienza E**, Eisdorfer C, Fordyce-Baum MK. Altered Folate Metabolism in Early HIV Infection. In Response to Tilkien et al. JAMA, 259:519, 1988.
3. **Mantero-Atienza E**, Beach RS, Fletcher M, van Riel F, Morgan R, Eisdorfer C, Fordyce-Baum MK. Measures of Nutritional Status in Early HIV Infection. Arch AIDS

Research, III:4;275-285, 1989.

4. Fordyce-Baum MK, Langer LM, **Mantero-Atienza E**, Crass R, Beach RS. Weight Reduction and Serum Lipid Profiles in Obese Females. Am J Clin Nutr, 50:30-6, 1989.
5. Millon C, Salvato F, Blaney N, Morgan R, **Mantero-Atienza E**, Klimas N, Fletcher, MA. A Psychological Assessment of Chronic Fatigue Syndrome/Chronic Epstein-Barr Virus Patients. Psychology and Health: An International Journal, 3:131-141, 1989.
6. Beach RS, **Mantero-Atienza E**, van Riel, F., Eisdorfer C, Fordyce-Baum MK. Implications of Nutritional Deficiencies in HIV Infection. I. Organ System Function in HIV Infection. Arch AIDS Research, III:4;287-306, 1989.
7. Beach RS, **Mantero-Atienza E**, Fordyce-Baum MK, Prineas R, Zelaya E, Thiebaud M, Loyola LA, Gosset G. HIV infection in Brazil. N Eng J Med, 321, 12:830-832, 1989.
8. Vergara A, Perez JM, Cruz E, Alvarez MM, Torres M, Perez FJ, Perez S, Molina JL, Bascañana A, **Mantero-Atienza E**. Epidemiology of AIDS in Cadiz, a south province of Spain. Arch AIDS Res, III:4;325-338, 1989.
9. Quintero JC, Moriana JCE, Moreno JMP, de Campos AV, Tortosa MT, Cortes SP, Palma MJC, Jimenez FJP, **Mantero-Atienza E**. Extrapulmonary Tuberculosis As AIDS Diagnosis Criterion. Arch AIDS Res, III:4;317-324, 1989.
10. Fordyce-Baum MK, **Mantero-Atienza E**, Morgan R, van Riel F, Beach RS. Toxic Levels of Dietary Supplementation in HIV-1 Infected Patients. Arch of AIDS Research, IV:1;149-158, 1990.
11. Beach RS, **Mantero-Atienza E**, van Riel, F., Fordyce-Baum MK. Potential Implications of Nutritional Deficiencies in HIV Infection. II. Nutrition, Immune Function and HIV Infection. Arch AIDS Research, IV:1;137-148, 1990.
12. **Mantero-Atienza E**, Baum MK, Javier JJ, Shor-Posner G, Millon C, Szapocznik J, Eisdorfer C, Beach RS. Nutritional Knowledge, Health Beliefs And Practices In The HIV Infected Patient. Nutr Res, 11;33-40, 1991.
13. **Mantero-Atienza E**, Baum M, Morgan R, Wilkie F, Shor-Posner G, Fletcher M, Eisdorfer C, Beach RS. Vitamin B₁₂ in early human immunodeficiency virus type 1 infection. Arch Int Med, 151:1019-20, 1991.
14. **Mantero-Atienza E**, Beach RS, Gavancho MC, Morgan R, Shor-Posner G, Baum MK. Selenium Status in Early HIV-1 Infection. JPEN, 15:693-94, 1991.
15. Hearn WL, Flynn DD, Hime GW, Rose S, Cofino JC, **Mantero-Atienza E**, Wetli CV, Mash DC. Cocaethylene: A Unique Cocaine Metabolite Displays High Affinity for the Dopamine Transporter. J Neurochem, 56,698-701, 1991.

16. Baum MK, **Mantero-Atienza E**, Fletcher MA, Morgan R, Eisdorfer C, van Riel F, Beach RS. Association of Vitamin B₆ Status with Parameters of Immune Function in Early HIV-1 Infection. J AIDS, 4:1122-32, 1991.
17. **Mantero-Atienza E**, Gavancho-Sotomayor M, Shor-Posner G, Fletcher MA, Sauberlich HE, Beach RS, Baum MK. Selenium Status and Immune Function in Asymptomatic HIV-1 Seropositive Men. Nutr Res, 11:11, 1236-50, 1991.
18. Baum MK, Javier JJ, **Mantero-Atienza E**, Beach RS, Sauberlich HE, Feaster D, Shor-Posner G. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-infected homosexual males. J AIDS, 4:1218-1226, 1991.
19. Beach RS, Morgan R, Wilkie F, **Mantero-Atienza E**, Eisdorfer C, Blaney N, Fordyce-Baum MK. Plasma Cobalamin Levels as a Potential Cofactor in Studies of HIV Related Cognitive Changes. Arch Neurol, 49:501-506, 1992.
20. Shor-Posner G, **Mantero-Atienza E**, Beach RS, Javier J, Feaster D, Sotomayor M, Cabrejos C, Fletcher MA, Lu Y, Sauberlich H, Baum MK. Association of Nutritional Abnormalities and Immune Parameters in HIV-1 Seronegative Homosexual Men. J Immunol Inf Dis, 2,4:209-216, 1992.
21. Beach RS, **Mantero-Atienza E**, Szapocznik J, Morgan R, Sauberlich HE, Eisdorfer C, Baum MK. Specific Nutrient Abnormalities in Asymptomatic HIV-1 Infection. J AIDS, 6:701-708, 1992.
22. Goodkin K, Blaney N, Feaster D, Fletcher MA, Baum, MK, **Mantero-Atienza E**, Klimas, Millon C, Szapocznik J, Eisdorfer C. Active coping style is associated with natural killer cell cytotoxicity in asymptomatic HIV-1 seropositive homosexual men. J Psychosomat Res, 36:7,635-650, 1992.
23. **Mantero-Atienza E**, Beach RS, Gavancho MC, Christakis G, Baum MK. Nutritional Status of Institutionalized Elderly in South Florida. Archivos Latinoamericanos de Nutricion, 42:3,242-249, 1992.
24. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Peck M, Chang J, Fletcher MA, **Mantero-Atienza E**, Baum MK. Hypcholesteremia is associated with immune dysfunction in early HIV-1 infection. Am J Med, 94(5) 515-519, 1993.
25. Peck M, **Mantero-Atienza E**, Beach RS, Cabrejos C, Lu Y, Shor-Posner G, Baum MK. The esterified plasma fatty acid profile is altered in early HIV-1 infection. Lipids, 28:7,593-597, 1993.
26. Bologna R, Indacochea F, Shor-Posner G, **Mantero-Atienza E**, Graziutti M, Sotomayor MC, Fletcher MA, Cabrejos C, Scott GB, Baum MK. Selenium and immunity in HIV-1 infected

pediatric patients. J Nutr Immunol, 3(1) 41-49, 1994.

27. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, **Mantero-Atienza E**. A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCL for Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 18(5):1162-1167, 1994.

BOOKS AND BOOK CHAPTERS:

1. Millon C, **Mantero-Atienza E**, Szapocznik J. "Psychological Junctions in HIV Infection" IN AIDS: An Environmental and System Approach, P.V. Stein, ed., Swets and Zeitlinger, 1989.
2. **Mantero-Atienza E**, Maitland T, Beach RS, Fordyce-Baum MK. "Nutritional Implications of Parkinson's Disease" Monograph of National Parkinson's Foundation, 1990.
3. Baum MK, Shor-Posner G, Bonvehi P, Cassetti I, Lu Y, **Mantero-Atienza E**, Beach RS, Sauberlich HE. Influence of HIV infection on vitamin status and requirements. New York Academy of Science, "Beyond Deficiency: New Views on the Function and Health Effects of Vitamins", Eds. Sauberlich, H.E., Machlin, L.J., 669:165-174, 1992.
4. Beach, R.S., Cabrejos, C., Shor-Posner, G., **Mantero-Atienza, E.**, Baum, M.K. "Nutritional Aspects of Early HIV Infection", In: Nutrition and Immunity, Eds. R.K. Chandra, 241-253, 1992.
5. Baum MK, Shor-Posner G, **Mantero-Atienza E**, Beach RS. "Nutrition Immune Function and HIV Infection," In WHO Psychoneuroimmunology and HIV-1 Disease. Eds. Schneiderman N, Szapocznik J, Antoni M, Eisdorfer C, Fletcher, MA, Goodkin K., and Maj M. Plenum, In Press, 1995.
6. Baum MK, Shor-Posner G, **Mantero-Atienza E**, Beach R.S. "The Acquired Immunodeficiency Syndrome; Nutritional Aspects of Neuropsychological Function and Disease Progression," In Stress, Coping and AIDS. Eds. Schneiderman N, McCabe P, Field T, and Eisdorfer C. Lawrence Erlbaum Assoc., Inc.; Hillsdale, N.J. In Press, 1995.

PUBLISHED ABSTRACTS:

1. **Mantero-Atienza E** & Pressman BC. Comparison of the effects of two dietary omega-3 lipids, linseed (18:3) and MaxEPA (20:5, 22:6) oils on blood lipids and blood pressure. Federation Proceedings 46:4, 1170, 1987.
2. Fordyce-Baum MK, **Mantero-Atienza E** and Christakis G. Nutritional status of elderly in a nursing home. Federation Proceedings 46:3, 900, 1987.

3. Eisdorfer C, Szapocznik J, Scott G, Klimas N, Fordyce-Baum MK, **Mantero-Atienza E** et al. The Biopsychosocial Research Center on AIDS: A multidisciplinary approach to the investigation of the AIDS disease, III International Conference on Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, USA. 1987.
4. **Mantero-Atienza E**, Eisdorfer C, Christakis G, Crass R and & Fordyce-Baum MK. Nutritional status and the development of AIDS in lymphadenopathy patients. III International Conference of Acquired Immunodeficiency Syndrome (AIDS), Washington, DC, USA. 1987.
5. **Mantero-Atienza E**, Christakis G, Fordyce-Baum MK. The effect of a Pectin containing food supplement on serum lipids and lipoproteins in healthy normolipidemic males. Proceedings of Southeastern Pharmacology Society, University, Mississippi. 1987.
6. Langer L, **Mantero-Atienza E**, Crass R, Duncan R, Fordyce-Baum MK. Effect of weight reduction by low-calorie diet on blood lipids in normolipidemic females. Proceedings of Southeastern Pharmacology Society, University, Mississippi. 1987.
7. **Mantero-Atienza E**, Pressman BC. Role of omega-3 Lipid Metabolism in Brain Functioning During Aging, Florida Council on Aging. American Federation on Aging Research, Ft. Lauderdale, Florida. 1987.
8. **Mantero-Atienza E**, Millon C, Beach RS. Psychosocial cofactors affecting HIV progression. First International Conference on the Global Impact of AIDS, London, England. 1988.
9. Beach RS, **Mantero-Atienza E**, Fordyce-Baum MK. Dietary supplementation in HIV infection. Federation Proceedings The FASEB Journal, Vol 2, No.5: #6618. 1988.
10. Fordyce-Baum MK, Beach RS, **Mantero-Atienza E**. Retinol-Binding protein in early HIV infection. Federation Proceedings The FASEB Journal, Vol 2, No.5: #6620. 1988.
11. **Mantero-Atienza E**, Fordyce-Baum MK, Beach RS. Elevated folate levels and immune function in early HIV infection. Federation Proceedings The FASEB Journal, Vol 2, No.6: #7742. 1988.
12. Crass R, **Mantero-Atienza E**, Beach RS, Fordyce-Baum MK. Weight loss and serum lipid modification by expanded wheat product. Federation Proceedings The FASEB Journal, Vol 4, No.4: #1941. 1988.
13. Beach RS, **Mantero-Atienza E**, Millon C. Psychosocial cofactors affecting HIV Progression. Proceedings First Pan American Conference on AIDS, Guadalajara, Mexico. 20:MS-4, 1988.
14. Beach RS, **Mantero-Atienza E**, Crass R, Fletcher MA, Morgan R, Eisdorfer C, Fordyce-Baum MK. Trace Elements during early HIV infection. Proceedings First Pan American Conference

- on AIDS, Guadalajara, Mexico. 24:P-8, 1988.
15. Beach RS, **Mantero-Atienza E**, Crass R, Fletcher MA, Morgan R, Eisdorfer C, Fordyce-Baum MK. Retinol-Binding protein in early HIV infection. Proceedings First Pan American Conference on AIDS, Guadalajara, Mexico. 25:P-9, 1988.
 16. Beach RS, **Mantero-Atienza E**, Crass R, Fletcher MA, Morgan R, Eisdorfer C, Fordyce-Baum MK. Elevated folate levels and immune function in early HIV infection. Proceedings First Pan American Conference on AIDS, Guadalajara, Mexico. 20:P-10, 1988.
 17. **Mantero-Atienza E**, Beach RS, Crass R, Fletcher MA, Morgan R, Fordyce-Baum MK. Retinol binding protein levels immune function: in HIV-1 infection. Proceedings Fourth International Conference on AIDS, Vol 2, #2608, 1988.
 18. Beach RS, **Mantero-Atienza E**, Crass R, Fletcher MA, Morgan R, Fordyce-Baum MK. Vitamin B₁₂ levels and immune function in early HIV infection. Proceedings Fourth International Conference on AIDS, Vol 2, #2601, 1988.
 19. Fordyce-Baum MK, **Mantero-Atienza E**, Crass R, Morgan R, Beach RS. Toxic levels on dietary supplementation in early HIV infection. Proceedings Fourth International Conference on AIDS, Vol 2, #7523, 1988.
 20. Yañez-Polo I, **Mantero-Atienza E**. Educational cooperation between Puerto Rico and Spain. Proceedings of the Ten years after Alma Ata: Health Progress, Problems and Future Priorities. 1988 Annual International Health Conference, Washington, DC. 1988.
 21. **Mantero-Atienza E**, Beach RS, Fordyce-Baum MK. Water-soluble vitamin levels in a geriatric population. J Clin. Pharmacol 28:Vol 28 #154, 1988.
 22. Beach RS, Fordyce-Baum MK, **Mantero-Atienza E**. Cholesterol and triglyceride levels in nursing home residents. J Clin Pharmacol 28:Vol 28, #153. 1988.
 23. Van Riel F, **Mantero-Atienza E**, Salvato F, Beach RS, Fletcher MA, Klimas N, Fordyce-Baum MK. Nutritional Status of Chronic Fatigue Syndrome (CFS)/Epstein-Barr Virus (EBV) patient. J. Exp. Clin. Cancer Res., 7,3,:88-Supplement. 1988.
 24. **Mantero-Atienza E**, van Riel F, Beach RS, Fordyce-Baum MK. Dietary Modification in HIV Seropositive Patients After Diagnosis. 2nd International Awareness Conference on AIDS, Arch of AIDS Res Vol III; 224, 1989.
 25. Beach RS, **Mantero-Atienza E**, Van Riel F, Fordyce-Baum MK. Potential Implications of Nutritional Deficiencies in Early HIV-1 Infected Patients. 2nd International Awareness Conference on AIDS, Arch of AIDS Res Vol III; 225, 1989.
 26. **Mantero-Atienza E**, Beach RS, van Riel F, Fordyce-Baum MK. Retinol-Binding Protein as an

- Early Predictor of Progression in the HIV Continuum. 2nd International Awareness Conference on AIDS, Arch of AIDS Res Vol III; 227, 1989.
27. **Mantero-Atienza E**, Beach RS, van Riel F, Fordyce-Baum MK. Nutritional Status of a Cohort of HIV-1 Positive Gay Men. Federation Proceedings, FASEB Meeting, A657:2502, 1989.
 28. Beach RS, **Mantero-Atienza E**, Eisdorfer C, Fletcher MA, Morgan R, Fordyce-Baum MK. Early Predictors of Nutritional Status In HIV-Infection. V International Conference on AIDS, Montreal, 467:Th.B.P. 306, 1989.
 29. **Mantero-Atienza E**, Beach RS, van Riel F, Fletcher MA, Morgan R, Eisdorfer C, Fordyce-Baum MK. Low Vitamin B6 Levels and Immune Dysregulation In HIV-1 Infection. V International Conference on AIDS, Montreal, 468:Th.B.P. 313, 1989.
 30. **Mantero-Atienza E**, Fordyce-Baum MK, van Riel F, Beach RS. Nutritional Knowledge Health Beliefs and Practices In The HIV-1 Infected Patient. V International Conference on AIDS, Montreal, 468:Th.B.P. 314, 1989.
 31. Beach RS, **Mantero-Atienza E**, van Riel F, Morgan R, Fordyce-Baum MK. Nutritional Abnormalities in Early HIV-1 Infection I. Plasma Vitamin Levels. V International Conference on AIDS, Montreal, 218:Th.B.P. 314, 1989.
 32. Fordyce-Baum MK, **Mantero-Atienza E**, van Riel F, Morgan R, Beach RS. Nutritional Abnormalities in Early HIV-1 Infection II. Trace Elements. V International Conference on AIDS, Montreal, 467:Th.B.P. 310, 1989.
 33. Beach RS, **Mantero-Atienza E**, Javier JJ, Fordyce-Baum MK. Nutritional Studies in Asymptomatic HIV-infected Patients. 14th International Congress of Nutrition, Seoul, Korea, 1989.
 34. Cabrejos C, **Mantero-Atienza E**, Fordyce-Baum MK, Beach RS, Javier JJ, Gavancho MC. Copper and immune status in early HIV-1 infection. Federation Proceedings, The FASEB Journal, Vol 4,No.3:#723, 1990.
 35. Chang J, Fordyce-Baum MK, Cabrejos C, Javier JJ, Beach RS, Gavancho MC, **Mantero-Atienza E**. Plasma fatty acids in early HIV-1 infection. Federation Proceedings, The FASEB Journal, Vol 4,No.3:#3070, 1990.
 36. **Mantero-Atienza E**, Javier JJ, Chang J, Beach RS, Gavancho MC, Cabrejos C, Fordyce-Baum MK. Levels of water soluble vitamins in patients with cystic fibrosis (CF). Federation Proceedings, The FASEB Journal, Vol 4,No.3:#2325, 1990.
 37. Gavancho M, **Mantero-Atienza E**, Mendoza E, Javier JJ, Cabrejos C, Beach RS, Fordyce-Baum MK. Riboflavin status in sickle cell disease (SCD). Federation Proceedings, The FASEB Journal, Vol 4,No.3:#3909, 1990.

38. Javier JJ, Fordyce-Baum MK, Beach RS, Gavancho MC, Cabrejos C, **Mantero-Atienza E**. Antioxidant micronutrients and immune function in HIV-1 infection. Federation Proceedings, The FASEB Journal, Vol 4, No. 4: #3911, 1990.
39. Javier JJ, Mavunda K, **Mantero-Atienza E**, Shor-Posner G, Baum MK. Trace Elements Status in Patients with cystic fibrosis (CF). Proceeding International CF Conference, Arlington, Virginia, 1990.
40. **Mantero-Atienza E**, Shor-Posner G, Mavunda K, Javier JJ, Baum MK. Inadequate fat soluble vitamin supplementation in cystic fibrosis (CF). Proceeding International CF Conference, Arlington, Virginia, 1990.
41. Javier JJ, Shor-Posner G, **Mantero-Atienza E**, Beach RS, Baum MK. Nutritional abnormalities associated with HIV Infection. Neuroscience Abstract, 16:614, 1990.
42. Shor-Posner G, Javier JJ, Beach RS, **Mantero-Atienza E**, Baum MK. Altered patterns of nutrient intake in HIV-1 + subjects with pyridoxine (Vitamin B₆) deficiency. Neuroscience Abstract, 16:614, 1990.
43. Javier JJ, Shor-Posner G, Cabrejos C, **Mantero-Atienza E**, Baum MK. Effects of Zidovudine (AZT) on trace element levels in HIV infections. J Clinical Pharmacology 1990; 30(9):840 #38.
44. Javier JJ, Chang J, Cabrejos C, **Mantero-Atienza E**, Behavioral changes and knowledge of HIV infected patients regarding diet, nutrition, and HIV infection. American Dietetic Association 73rd Annual Meeting, Denver, Colorado, #A-70, 1990.
45. **Mantero-Atienza E**, Baum MK, Beach RS, Javier JJ, Morgan R, Eisdorfer C. Vitamin B₆ and immune function in HIV infection. VI International Conference on AIDS, San Francisco. Vol 2, #3123, 1990.
46. Baum MK, Beach RS, Morgan R, **Mantero-Atienza E**, Wilke F, Eisdorfer C. Vitamin B₁₂ and cognitive function in HIV infection. VI International Conference on AIDS, San Francisco. Vol 2, #F.B. 32, 1990.
47. Beach RS, Baum MK, Shultz J, **Mantero-Atienza E**, Prineas RJ, Thiebaud-Alvarenga M, Alvarenga JC, Gutierrez R, Tercero D, Zelaya E. Patterns of HIV-Infection in Central America. VI International Conference on AIDS, San Francisco. Vol 2, #F.C. 590, 1990.
48. Baum MK, Beach RS, Morgan R, **Mantero-Atienza E**, Wilke F, Eisdorfer C. Vitamin B₁₂ and cognitive function in HIV infection. PSY-9. Neurological and Neuropsychological Complications of HIV infection. Monterey, California, 1990.
49. **Mantero-Atienza E**, Sotomayor MC, Shor-Posner G, Fletcher MA, Beach R, Basit A, Cabrejos C, Baum MK. Selenium status and immune function in early HIV-1 infection. VII

International Conference on AIDS, Florence, Italy, Vol 1, #M.C.3126, 329, 1991.

50. Baum MK, Beach RS, **Mantero-Atienza E**, Fletcher M, Rosner B, Eisdorfer C, Shor-Posner G. Predictors of change in immune function: longitudinal analysis of nutritional status in early HIV-1 infection. VII International Conference on AIDS, Florence, Italy, Vol 1, #M.C.3127, 329, 1991.
51. Beach RS, Cabrejos C, **Mantero-Atienza E**, Basit A, Chang J, Fletcher M, Baum MK. Effect of zinc normalization on immunological function in early HIV-1 infection. VII International Conference on AIDS, Florence, Italy, Vol 1, #M.C.3128, 330, 1991.
52. Shor-Posner G, **Mantero-Atienza E**, Beach R, Javier JJ, Basit A, Cabrejos C, Sauberlich HE, Feaster D, Baum MK. Zidovudine-associated alterations in nutrient status: impact upon immune function. VII International Conference on AIDS, Florence, Italy, Vol 2, #W.B.2098, 206, 1991.
53. Indacochea FJ, Zambrano JC, **Mantero-Atienza E**, Scott GB. Selenium deficiency in HIV-infected children. Proceedings American Pediatric Society Meeting, 1991.
54. Mavunda K, Javier JJ, **Mantero-Atienza E**, Shor-Posner G, McKey RM. Trace elements in patients with cystic fibrosis (CF). Proceedings American Pediatric Society Meeting, 1991.
55. **Mantero-Atienza E**, Mavunda K, Shor-Posner G, Javier JJ, Baum MK. Inadequate fat soluble vitamin supplementation in cystic fibrosis (CF). Proceedings American Pediatric Society JAIDS,4:1122-32, 1991.
56. Cabrejos C, Shor-Posner G, **Mantero-Atienza E**, Beach R, Basit A, Chang J, Baum MK. Altered levels of fatty acids affect immune function in early HIV-1 infection. Proceedings American Association of Pharmaceutical Scientists, 1991.
57. Basit Abdul, **Mantero-Atienza E**, Beach RS, Cabrejos C, Chang J, Shor-Posner G, Baum MK. Lipid Status in Early HIV-1 Infection. Proceedings American Association of Pharmaceutical Scientists, 1991.
58. Wilkie F, Shor-Posner G, **Mantero-Atienza E**, Beach RS, Ayala M, Morgan R, Eisdorfer C, Baum MK. Association of vitamin B₆ status and reaction time in early HIV-1 infection. International conference on Neuroscience of HIV Infection, Padova, Italy 1991.
59. Chang J, Shor-Posner G, Cabrejos C, Baum MK, **Mantero-Atienza E**. Alterations in Body Composition in HIV-1 Infection. 74th Annual Meeting. Proceedings of The American Dietetic Association, In press, 1991.
60. Shor-Posner G, Ramsay RE, Morgan R, Slater J, Beach R, **Mantero-Atienza E**, Baum MK.

Association of Electrophysiologic Brain Function and Nutritional Status in Human Immunodeficiency Virus (HIV-1) Infection. 21st Ann Mtng. Society for Neurosciences, Vol 1, #13.12, 22, 1991.

61. Singer C, **Mantero-Atienza E**, Weiner W. Tandem Gait in Middle Aged and Elderly Subjects: A Normative Study. Proceedings 1992 AAN Scientific Program, 1991.
62. Baum MK, Shor-Posner G, Cassetti I, Bonvehi P, Lu Y, Beach RS, **Mantero-Atienza E**. Influence of HIV-1 Infection on vitamin status and requirements. Proceedings of the New York Academy of Science, 1992.
63. Peck M, Cabrejos C, Basit A, Chang J, **Mantero-Atienza E**, Beach R, Lu Y, Shor-Posner G, Baum MK. Desaturations and elongation of linoleic acid is impaired in early HIV-1 infection. Proceedings 3rd International Congress on Essential Fatty Acids, Australia, 1992.
64. **Mantero-Atienza E**, Indacochea F, Cabrejos C, Sotomayor MC, Fletcher MA, Sauberlich HE, Shor-Posner G, Baum MK. Selenium deficiency associated with HIV-1 infection in children. VIII International Conference on AIDS, Amsterdam, Netherlands, Vol 3, PuB, 7336, 1992.
65. Baum MK, Shor-Posner G, Cassetti LI, Lu Y, **Mantero-Atienza E**, Beach RS, Sauberlich HE. Interim dietary recommendations to maintain adequate blood nutrient levels in early HIV-1 infection. VIII International Conference on AIDS, Amsterdam, Netherlands, Vol 3, PoB, 3675, 1992.
66. Shor-Posner G, Blaney N, Feaster D, **Mantero-Atienza E**, Beach RS, Sauberlich H, Goodkin K, Eisdorfer C, Baum MK. Anxiety and depression in early HIV-1 infection and its association with vitamin B₆ status. VIII International Conference on AIDS, Amsterdam, Netherland, Vol 2, PoB, 3711, 1992.
67. Singer C, **Mantero-Atienza E**, Weiner WJ. A novel rating scale for evaluation of tandem gait. study of interrater reliability and comparison of normal subjects with parkinsonian and essential tremor patients. 2nd International Congress of Movement Disorders, Vol 7, Supple 1, P292, 1992.
68. Shor-Posner G, Morgan R, Wilkie F, Beach RS, **Mantero-Atienza E**, Baum MK. Plasma cobalamin levels are associated with information processing speed in a longitudinal study of HIV-1 disease. Society for Neuroscience, Vol 1, 144.13 1992.
69. Singer C, **Mantero-Atienza E**, Weiner WJ. Tandem gait in Parkinson's disease. Proceedings American Neurological Association, 1993.
70. Shor-Posner G, Miguez-Burbano MJ, **Mantero-Atienza E**, Fletcher MA, Baum MK. Elevated IgE in relationship to plasma vitamin E levels in early HIV-1 disease. IX International Conference on AIDS, Berlin, Germany, 1993.

71. Wolfgang Fleischhacker, Jana Podhorna, Martina Groschl, Sanjay Hake, Yihua Zhao, Ronald Brenner, David Walling, Kazuyuki Nakagome, **Emilio Mantero-Atienza**, Stephane Pollentier. Efficacy and safety of BI 425809 once daily in patients with schizophrenia: Topline Phase 2 results. SIR 2020 1346-0009 abstract Draft 1.

CLINICAL RESEARCH EXPERIENCE:

Alzheimer's disease

- 2018-Present Principal Investigator
A Multi-Center, Double-Blind, Parallel-Group, Randomized Controlled Study to Investigate Efficacy and Safety of Orally Administered “Study Drug” during a 12-week Treatment Period Compared to Placebo in Patients with Cognitive Impairment due to Alzheimer's Disease.
- 2017-Present Principal Investigator
Open Label Extension Study for Continued Safety and Efficacy Evaluation of in “Study Drug” Patients with Mild Alzheimer's Disease.
- 2017-Present Principal Investigator
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of “Study Drug” in Subjects with Early Alzheimer's Disease.
- 2016-Present Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of “Study Drug” in the Treatment of Agitation in Patients with Dementia.
- 2016-Present Principal Investigator
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of “Study Drug” for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type.
- 2016-Present Principal Investigator
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of “Study Drug” for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type.
- 2015-2017 Principal Investigator
A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 mg and 100 mg of “Study Drug” in Subjects with Moderate Alzheimer's.

- 2015-Present Principal Investigator
Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of “Study Drug” in Patients with Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.
- 2015-2017 Principal Investigator
Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study of “Study Drug” in Patients with Mild-Moderate Alzheimer's Disease Treated with an Acetylcholinesterase Inhibitor; Study 3.
- 2015-2015 Principal Investigator
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of “Study Drug” or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication.
- 2014-2017 Principal Investigator
A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer's Type who were Previously Treated with “Study Drug” or Placebo in a Phase 3, Double-blind Trial
- 2014-2015 Sub-Investigator
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of “Study Drug” or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor.
- 2014-Present Principal Investigator
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of “Study Drug” in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type.
- 2014-2014 Principal Investigator
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of “Study Drug” for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
- 2013-2014 Sub-Investigator
A Multicenter Prospective Observational Study to Assess Resource Utilization and Health-related Quality of Life in Patients with Alzheimer's Disease Receiving “Study Drug” – Strength Study.
- 2013-2014 Sub-Investigator
A Multicenter Prospective Observational Study to Assess Resource Utilization and

Health-Related Quality of Life in Patients with Alzheimer's Disease of "Study Drug"
– Strength Study.

- 2011- 2013 Principal Investigator
An Evaluation of the Safety and Efficacy of Memantine in agitated Patients With Moderate to Severe Alzheimer's Disease.
- 2010-2011 Sub-Investigator
Efficacy and Safety of "Study Drug" Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease.
- 2008-2010 Sub-Investigator
Study of "Study Drug" in the Treatment of Patients With Psychosis Associated With dementia of the Alzheimer's type.

Bipolar Disorder

- 2017-Present Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of "Study Drug" in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression).
- 2017-Present Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of "Study Drug" Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression).
- 2013-2013 Principal Investigator
Open-label Study to Evaluate the Effectiveness of "Study Drug" Formulation of Aripiprazole as Maintenance Treatment in Patients with Bipolar I Disorder.
- 2008-2008 Sub-Investigator
Single center, open prospective study to evaluate the effectiveness of "Study Drug" monotherapy in the maintenance treatment of adolescent patients with bipolar spectrum disorder (bipolar I and bipolar II disorders, cyclothymia, and bipolar disorder not otherwise specified).
- 2003-2005 Principal Investigator
Double-Blinded Randomized Endpoint Classification Safety/Efficacy Study of the effectiveness and Safety of "Study Drug" in the Treatment of Mania/Bipolar Disorder.
- 2003-2004 Principal Investigator
Double-Blind Randomized Placebo-Controlled Trial of "Study Drug" in Treatment of

Resistant Bipolar Depression.

Major Depression Disorder

- 2011-2012 Principal Investigator
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of “Study Drug” as Adjunctive Therapy in Adults With Major Depressive Disorder.
- 2010-2012 Principal Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with “Study Drug” in Patients With Major Depressive Disorder.
- 2010-2010 Sub-Investigator
To determine effect sizes on scales measuring depressive symptoms, physical symptoms, psychosocial function and quality of life, and to evaluate safety in the population of patients with epilepsy.
- 2007-2008 Sub-Investigator
To determine the safety and efficacy of “Study Drug” Monotherapy in the treatment of major depressive disorder with psychotic features.

Traumatic Brain Injury

- 2017-Present Principal Investigator
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of “Study Drug” for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients with Traumatic Brain Injury (TBI).

Schizophrenia

- 2018-Present Principal Investigator
A Phase II Randomized, Double-Blinded, Placebo-Controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of “Study Drug” Once Daily over 12 week Treatment Period in Patients with Schizophrenia.
- 2017-Present Principal Investigator
A Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing Paliperidone Palmitate Extended-release “Study Drug” with Invega Sustenna (US Product Reference) in Subjects with Schizophrenia or Schizoaffective Disorder.
- 2017-Present Principal Investigator
Interventional ,Open-Label, Flexible Dose, Long Term Safety Study of “Study Drug”

in Adult Patients with Schizophrenia.

- 2016-Present Principal Investigator
An Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of “Study Drug” in Patients with Schizophrenia.
- 2016-Present Principal Investigator
Interventional, randomised, Double-Blind, Active-Controlled, Fixed-Dose Study of “Study Drug” in Patients with Treatment-Resistant Schizophrenia.
- 2015-2017 Principal Investigator
A Phase 2, Efficacy, Safety, and Tolerability Study of “Study Drug” in Schizophrenia with Alcohol Use Disorder Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride.
- 2015-2016 Principal Investigator
An Open-Label, Long-Term Safety and Tolerability Study of “Study Drug” in the Treatment of Subjects with Schizophrenia.
- 2014-2015 Principal Investigator
A 26-Week Extension Study of “Study Drug” as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
- 2014-2016 Principal Investigator
Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety “Study Drug” Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents.
- 2013-2014 Principal Investigator
Randomized, double blind, placebo controlled, parallel 26 week phase III study of 2 doses of an “Study Drug” or placebo as an adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on chronic stable atypical antipsychotic therapy.
- 2012- 2013 Principal Investigator
An open-label, multi-center, pilot, multiple-dose, bioavailability study to determine the pharmacokinetics of “Study Drug” injection 117 mg/0.75 ml in subjects with schizophrenia.
- 2011-2012 Sub-Investigator
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months.

- 2008-2009 Sub-Investigator
Evaluation of “Study Drug” cognitive effects in a pilot placebo controlled trial in patients with Schizophrenia.
- 2004-2005 Sub-Investigator
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM “Study Drug”.

Tardive Dyskinesia

- 2015-2016 Principal Investigator
A Phase 3, Open-Label, Safety and Tolerability Study of “Study Drug” NBI-98854 for the Treatment of Tardive Dyskinesia.
- 2014-2015 Sub-Investigator
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered “Study Drug” in Subjects with Drug-Induced Tardive Dyskinesia
- 2013-2014 Principal Investigator
A randomized endpoint classification: pharmaco-dynamics study to assess the risk of experiencing Tardive Dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients
- 2008-2010 Sub-Investigator
Evaluation of efficacy and tolerability of switching to Ziprasidone from other antipsychotic medications in the population of patients with Tardive Dyskinesia
- 2005-2005 Principal Investigator
Double-Blinded Randomized Endpoint Classification Safety/Efficacy Study of the effectiveness and Safety of “Study Drug” in the Treatment of Tardive Dyskinesia.

Diabetes

- 2010-2012 Sub-Investigator
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of “Study Drug” in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).